NeuroVax Launches Trial of MS Vaccine
Posted on: Tuesday, 10 October 2006, 12:00 CDT
U.S. firm Immune Response Corp. said Tuesday it has secured a contractor for its phase 2 trial of NeuroVax, a vaccine for multiple sclerosis.
The company said it has contracted with Accelsiors CRO & Consultancy Services to oversee the study.
IRC said it would start enrolling patients in the study by the end of the year, eventually recruiting 200 subjects with relapsing-remitting MS.
The study will be powered to compare the cumulative number of new gadolinium enhancing brain lesions -- a key marker of the disease -- via manetic resonance imaging scans at 24, 32, 40, and 48 weeks.
We are extremely excited at the potential of NeuroVax(TM) to help patients with Multiple Sclerosis, said Krzysztof Selmaj, the study's lead investigator. This treatment may have the ability to alter how the immune system fights MS and we eagerly anticipate study results that could offer benefit to the millions of MS patients in need of more effective and tolerable treatment options.
NeuroVax is a T-cell receptor (TCR) peptide vaccine.
According to IRC, MS affects about 400,000 people in the United States and roughly 2.5 million people worldwide.
Source: United Press International
Related Articles
- SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia
- Results From Largest Statin Study of Patients With Alzheimer's Disease Show Lipitor(R) Has No Significant Impact on Disease
- Results of Sepracor's LUNESTA(R) Next-Day Driving Study in Patients With Primary Insomnia Presented at American College of Neuropsychopharmacology Meeting
- ZymoGenetics Releases Preliminary Findings From Atacicept (TACI-Ig) Phase 1b Studies in Patients With Lupus
- Rigel Announces Completion of R788 Plus Methotrexate Drug Interaction Study in Patients With Rheumatoid Arthritis
- Web Seminar Offered -- ''EHR Case Study: Delivering Patient Data Today''
- ZymoGenetics Reports Preliminary Positive Results From TACI-Ig Phase 1b Study in Patients With Rheumatoid Arthritis
- New Study Suggests Patients With Schizophrenia Improved With Treatment Change to RISPERDAL(R) CONSTA(R)
- IL-1 Trap Shows Positive Results in Study of Patients With Inflammatory Disease
- Updated Survival Results From BLP25 Liposome Vaccine (L-BLP25) Phase IIb Study From Patients With Stage IIIB Non-Small Cell Lung Cancer (NSCLC) Presented
 |
 |
User Comments (0)
RSS Feeds